Iberiabank Corp bought a new position in shares of Mednax, Inc (NYSE:MD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,512 shares of the company’s stock, valued at approximately $318,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Eagle Boston Investment Management Inc. raised its stake in Mednax by 12.9% during the 2nd quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock worth $11,569,000 after acquiring an additional 21,895 shares during the period. Prudential Financial Inc. raised its position in shares of Mednax by 976.9% during the third quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock valued at $27,642,000 after buying an additional 581,527 shares during the last quarter. Swiss National Bank raised its position in shares of Mednax by 3.0% during the second quarter. Swiss National Bank now owns 341,700 shares of the company’s stock valued at $20,628,000 after buying an additional 9,900 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of Mednax during the second quarter valued at approximately $347,000. Finally, South Dakota Investment Council raised its position in shares of Mednax by 24.5% during the second quarter. South Dakota Investment Council now owns 50,800 shares of the company’s stock valued at $3,067,000 after buying an additional 10,000 shares during the last quarter. Institutional investors own 98.44% of the company’s stock.

MD has been the topic of several recent analyst reports. BidaskClub cut shares of Mednax from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Robert W. Baird reiterated a “hold” rating and set a $47.00 price objective on shares of Mednax in a research report on Sunday, September 3rd. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. KeyCorp set a $51.00 price objective on shares of Mednax and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. Mednax currently has a consensus rating of “Hold” and an average target price of $54.50.

In other news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Mednax, Inc (NYSE MD) traded down $0.77 during midday trading on Tuesday, reaching $48.33. 1,287,500 shares of the company’s stock traded hands, compared to its average volume of 1,055,748. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $4,598.47, a price-to-earnings ratio of 15.02, a price-to-earnings-growth ratio of 1.58 and a beta of 0.32. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13.

Mednax (NYSE:MD) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the consensus estimate of $0.87. The company had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. Mednax’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.09 earnings per share. research analysts anticipate that Mednax, Inc will post 3.1 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/28/7512-shares-in-mednax-inc-md-purchased-by-iberiabank-corp.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.